Patents Issued in March 17, 2020
  • Patent number: 10590173
    Abstract: A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a polyprotein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polyprotein is also provided.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 17, 2020
    Assignee: Medicago Inc.
    Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Manon Couture, Lucie Poulin, Louis-Philippe Vezina
  • Patent number: 10590174
    Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: March 17, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LA REUNION SAINT DENIS, INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Gilles Gadea, Michael Girardot, Philippe Despres
  • Patent number: 10590175
    Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: March 17, 2020
    Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
  • Patent number: 10590176
    Abstract: The present disclosure provides compositions and methods for preparing engineered porous protein crystals comprising at least one guest molecule.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: March 17, 2020
    Assignee: Colorado State University Research Foundation
    Inventors: Christopher D. Snow, Thaddaus R. Huber
  • Patent number: 10590177
    Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions elated to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: March 17, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 10590178
    Abstract: Chimeric double peptide vaccines are disclosed, useful for inducing active immunity against Candida fungal infections. The chimeric peptide comprises an Fba peptide and an Met6 peptide, covalently linked to one another, with or without an intermediate linker. Fba and Met6 are cell surface components of Candida. When used as a vaccine, the chimeric double peptide vaccine induces stronger protective immunity against fungal infection than does the Fba peptide alone, or the Met6 peptide alone, or a mixture (not covalently linked) of the two peptides.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: March 17, 2020
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Hong Xin
  • Patent number: 10590179
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: March 17, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Patent number: 10590180
    Abstract: The present invention discloses immune function development promoters and growth promoters comprising CCL25. The development of immune functions in a subject can be promoted by ingesting an immune function development promoter according to the present invention. Moreover, growth of a subject can be promoted by ingesting a growth promoter according to the present invention.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: March 17, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY
    Inventor: Kazutoshi Sayama
  • Patent number: 10590181
    Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of mutant light-activated ion channels and variants thereof.
    Type: Grant
    Filed: April 18, 2015
    Date of Patent: March 17, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Edward S. Boyden, Yongku Peter Cho, Nathan C. Klapoetke, Amy S. Chuong, Fei Chen
  • Patent number: 10590182
    Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Wendell A. Lim, Leonardo Morsut, Kole T. Roybal, Justin Thomas Farlow, Satoshi Toda
  • Patent number: 10590183
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: March 17, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
  • Patent number: 10590184
    Abstract: This invention reveals the potential applications of modified porcine plasma fibronectin that could be applied as a safe material for clinical wound healing and tissue repair. In order to seek safe sources of plasma fibronectin for practical consideration in wound dressing, this invention isolated and modified fibronectin from porcine plasma and demonstrated that modified porcine plasma fibronectin has similar ability as homo plasma fibronectin being as a suitable substrate for stimulation of cell adhesion and directed cell migration. The present invention also reveals a material and a pharmaceutical composition enhance wound healing.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: March 17, 2020
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventor: Jean-Cheng Kuo
  • Patent number: 10590185
    Abstract: A genetically engineered live bacterium which is adapted to selectively replicate in and colonize a selected tissue type within the mammal, and concurrently produce within the selected tissue type at least one protease-sensitive cytotoxic molecule which is degradable by proteases within the selected tissue type, and at least one protease inhibitor peptide to inhibit the proteases within the selected tissue type from proteolytically degrading the protease sensitive cytotoxic molecule. The combination results in higher concentrations of the cytotoxic molecule local to the colonization, while permitting protease degradation of the cytotoxic molecule further away from the colonization.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: March 17, 2020
    Inventor: David Gordon Bermudes
  • Patent number: 10590186
    Abstract: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric and in aggregated form to a cation exchange material under conditions whereby the immunoglobulin in monomeric form does not bind to the cation exchange material, and recovering the immunoglobulin in monomeric form from the solution after the contact with the cation exchange material.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: March 17, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Roberto Falkenstein, Claudia Giessel
  • Patent number: 10590187
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 17, 2020
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • Patent number: 10590188
    Abstract: The present invention provides an antibody which comprises a variable heavy (VH) chain comprising CDR1, CDR2 and CDR3, and/or a variable light (VL) chain comprising CDR1, CDR2 and CDR3, wherein the CDRs have the same amino acid sequence as those from a complete antibody isolated from a synovial tissue sample of rheumatoid arthritis patients, as listed in Tables 1 and 2 or Tables 1 A and 2 A.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: March 17, 2020
    Assignee: Queen Mary University of London
    Inventors: Michele Bombardieri, Constantino Pitzalis, Elisa Corsiero
  • Patent number: 10590189
    Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: March 17, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
  • Patent number: 10590190
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 17, 2020
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Patent number: 10590191
    Abstract: The invention relates to anti-Tau nanobodies.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 17, 2020
    Assignees: UNIVERSITE GRENOBLE ALPES, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Daniel Fagret, Marcelle Moulin, Catherine Ghezzi, Pascale Perret, Sabine Chierici
  • Patent number: 10590192
    Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 17, 2020
    Assignee: CELLMID LIMITED
    Inventors: Maria Halasz, Darren Jones, Nico Mertens, Phillip Cunnah
  • Patent number: 10590193
    Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: March 17, 2020
    Assignee: Novartis AG
    Inventors: Leonardo Borras, David Urech, Tea Gunde
  • Patent number: 10590194
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 17, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Claudia Wagner, Leonie Alten, Sebastian Bunk, Dominik Maurer
  • Patent number: 10590195
    Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 17, 2020
    Assignee: VACCIBODY AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Patent number: 10590196
    Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 17, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • Patent number: 10590197
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: March 17, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • Patent number: 10590198
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: March 17, 2020
    Assignee: Alector LLC
    Inventors: Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
  • Patent number: 10590199
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: March 17, 2020
    Assignee: CHECKPOINT THERAPEUTICS, INC.
    Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
  • Patent number: 10590201
    Abstract: Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: March 17, 2020
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard M. Siegel, Francoise Meylan, Yun-Jeong Song
  • Patent number: 10590202
    Abstract: A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: March 17, 2020
    Assignee: BALIOPHARM AG
    Inventors: Andreas Herrmann, Ludger Grosse-Hovest
  • Patent number: 10590203
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: March 17, 2020
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Patent number: 10590204
    Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: March 17, 2020
    Assignee: KATINGER GMBH
    Inventors: Hermann Katinger, Renate Kunert, Thomas Sterovsky, Thomas Hemetsberger
  • Patent number: 10590205
    Abstract: Provided herein are compositions, which exhibit diagnostic capabilities and allow to rapidly add functionality to adoptive immunotherapy. The compositions include isolated nucleic acids encoding proteins including antibody regions capable of binding compounds including a peptidyl moiety (e.g., a meditope). The recombinant proteins provided herein are useful, inter alia, for a broad variety of therapeutic and diagnostic purposes. For example, the recombinant proteins provided herein including embodiments thereof may be used as non-invasive means to characterize chimeric antigen receptor (CAR) T cells before and/or during treatment of diseases (e.g., cancer).
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: March 17, 2020
    Assignee: CITY OF HOPE
    Inventors: John C. Williams, Christine Brown
  • Patent number: 10590206
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: March 17, 2020
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
  • Patent number: 10590207
    Abstract: The present invention is directed to a process for obtaining at least one of fucoidan and laminarin from live, harvested seaweed, wherein the process comprises the steps of: (i) harvesting seaweed comprising fucoidan and laminarin to obtain live, harvested seaweed, wherein the live, harvested seaweed exudes to form an exudate solution; (ii) collecting the exudate solution from the live, harvested seaweed, wherein the fucoidan and laminarin are dissolved in the exudate solution; and (iii) separating the at least one of fucoidan or laminarin from the exudate solution.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: March 17, 2020
    Inventors: Finn Hjelland, Arne Henning Andersen, Hui S. Yang
  • Patent number: 10590208
    Abstract: A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer to form a reactive polymer, and (ii) reacting the reactive polymer with an imine compound containing a cyano group.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: March 17, 2020
    Assignee: Bridgestone Corporation
    Inventors: Steven Luo, Joshua S. Dickstein
  • Patent number: 10590209
    Abstract: A catalyst composition for selectively hydrogenating a conjugated diene polymer in a homogeneous system is provided, wherein the conjugated diene polymer comprises a conjugated diene monomer or a combination of a conjugated diene monomer and a vinyl aromatic monomer. The catalyst composition includes the catalyst components of (a) a titanium compound; (b) an organometallic compound; and (c) an oligomer containing a polyglycol segment. The hydrogenated polymer produced using the catalyst composition and the method thereof is also provided.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: March 17, 2020
    Assignee: TSRC Corporation
    Inventors: Kuoyu Weng, Fengyu Yang, Wenhsien Wen, Ching Ting, Ting-Yu Lee
  • Patent number: 10590210
    Abstract: A method for producing chlorinated polyvinyl chloride includes bringing chlorine gas into contact with a mixture comprising a polyvinyl chloride powder and at least one inorganic filler; and irradiating the mixture with UV light to perform a chlorination reaction. At least one inorganic filler is selected from the group consisting of silica, carbon black, and talc.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: March 17, 2020
    Assignee: KANEKA CORPORATION
    Inventors: Junichi Hirota, Yoshito Takeuchi, Naoki Deguchi
  • Patent number: 10590211
    Abstract: A method for producing a solid catalyst component includes bringing a magnesium compound, a titanium halide compound, and one or more internal electron donor compounds into contact with each other to effect a reaction; washing the resulting product with a first inert organic wash solvent that does not have reactivity with the titanium halide compound, and has a solubility parameter (SP) of 8.0 to 9.0; washing the resulting intermediate product in the absence of the titanium halide compound with a second inert organic wash solvent that includes a hydrocarbon compound and does not have reactivity with the titanium halide compound, but has a solubility parameter (SP) of more than 9.0; and washing the resulting product in the absence of the titanium halide compound with a third inert organic wash solvent that does not have reactivity with the titanium halide compound, and has a solubility parameter (SP) of less than 8.0.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 17, 2020
    Assignee: TOHO TITANIUM CO., LTD.
    Inventors: Motoki Hosaka, Toshihiko Sugano, Tsutomu Uzawa
  • Patent number: 10590212
    Abstract: This invention relates to new multimodal and/or broad molecular weight high density polyethylene polymers. The polymers may be made in a single reactor, preferably a gas phase reactor using a dual catalyst system comprising a pyridyldiamido transition metal compound, a metallocene compound, a support, and optionally an activator.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: March 17, 2020
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Antonios K. Doufas, David F. Sanders, Alexander I. Norman, Matthew W. Holtcamp, Keith R. Green, Rohan A. Hule, Derek W. Thurman
  • Patent number: 10590213
    Abstract: Disclosed herein are ethylene-based polymers generally characterized by a density of at least 0.94 g/cm3, a high load melt index from 4 to 20 g/10 min, a zero-shear viscosity at 190° C. from 20,000 to 400,000 kPa-sec, and a relaxation time at 190° C. from 225 to 3000 sec. These ethylene polymers can be produced by peroxide-treating a broad molecular weight distribution Ziegler-catalyzed resin, and can be used in large diameter, thick wall pipes and other end-use applications.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 17, 2020
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Vivek Rohatgi, Ashish M. Sukhadia, Yongwoo Inn, Elizabeth M. Lanier
  • Patent number: 10590214
    Abstract: The various embodiments of the invention provide, a magnesium titanium polymerization procatalyst, methods for making and using the same.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: March 17, 2020
    Assignee: NOVA Chemicals (International) S.A.
    Inventors: Qinyan Wang, Helena Ouskine, Mohamed Aiffa, Amy Baltimore, Holly Severin, Perry Dewit, Steven Clemens, Lawrence Martin Josef Van Asseldonk, Isam Jaber
  • Patent number: 10590215
    Abstract: The present disclosure provides a novel transition metal compound having excellent structural stability together with polymerization reactivity, and thereby is useful as a catalyst in preparing an olefin-based polymer, particularly, a high molecular weight and low density olefin-based polymer, and a catalyst composition including the same.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: March 17, 2020
    Assignee: LG CHEM, LTD.
    Inventors: Yoon Hee Cho, Jin Sam Gong, Jung Ho Jun, Choong Hoon Lee, Seung Hwan Jung
  • Patent number: 10590216
    Abstract: The present invention relates to a method for producing a vinyl chloride-based resin composition which exhibits good processability due to excellent solubility in a solvent, can implement excellent transparency in products produced, and improves the glossiness of a coating film when used as an ink binder, thereby being capable of being used as a high-quality adhesive and ink binder, and a method for producing the same.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: March 17, 2020
    Assignee: HANWHA CHEMICAL CORPORATION
    Inventors: Ji Won Kim, Jeong Hwan Ko, Paul Kang
  • Patent number: 10590217
    Abstract: Provided are a curable compound, a photoinitiator, and a curable resin composition comprising at least two types of thermal initiators, each having different initiation reaction temperature. Since the curable resin composition can improve a curing rate while having a high conversion rate, the curable resin composition is suitable for manufacturing thick films.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: March 17, 2020
    Assignee: LG HAUSYS, LTD.
    Inventors: Dong Kwan Kim, Min Hee Lee
  • Patent number: 10590218
    Abstract: Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a crosslinker monomer or oligomer having more than two polymerizable groups. Devices formed from radiopaque polymer compositions are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 17, 2020
    Assignee: ENDOSHAPE, INC.
    Inventors: Stephen D. Goodrich, Jeffrey P. Castleberry
  • Patent number: 10590219
    Abstract: A retardation material-forming resin composition for providing an orientation material that has high photoreaction efficiency and with which a polymerizable crystal can be aligned in a highly sensitive manner. A retardation material-forming resin composition being thermally curable wherein including a resin (component (A)) having a photo-aligning group to which a thermally reactive moiety is bonded directly or connected via a linking group; an orientation material obtained by use of the composition, and a retardation material formed by use of a cured film obtained from the composition.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: March 17, 2020
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Shojiro Yukawa, Jun Ito, Kohei Goto, Yuta Kanno, Hiroyuki Omura, Tadashi Hatanaka
  • Patent number: 10590220
    Abstract: The present disclosure provides for new photoalignment (co)polymer materials which demonstrate improved adhesion to a substrate. The (co)polymeric structure includes at least one photochemically active chromophore and at least one adhesion promoter group. Articles of manufacture, optical elements, ophthalmic elements and liquid crystal cells which include at least one photoalignment layer made from the photoalignment (co)polymer materials and methods for formation are also disclosed.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: March 17, 2020
    Assignee: Transitions Optical, Inc.
    Inventors: Gobinda Saha, Anil Kumar
  • Patent number: 10590221
    Abstract: Provided is a modified diene based polymer in which a diene based polymer is graft modified with a polyether having a mercapto group attached via diurethane bonding. Formation of diurethane bonding is performed by allowing sequential reactions of two species of hydroxyl group-containing compounds with an diisocyanate compound. By adding the modified diene based polymer to a silica-containing rubber composition for automobile pneumatic tires, the dispersibility of silica compounded in the rubber composition can be improved, and a property inherent in silica which simultaneously allows a reduction of rolling resistance and a stability on wet road surfaces can be sufficiently effected.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: March 17, 2020
    Assignee: The Yokohama Rubber Co., Ltd.
    Inventors: Kazuya Uenishi, Takahiro Okamatsu, Ryota Takahashi
  • Patent number: 10590222
    Abstract: The present invention is to provide a thermoplastic resin composition capable of obtaining a molded article that is excellent in appearance after laser welding and a color tone and has sufficient impact property as a resin member. In addition, the present invention is to provide a molded article that is excellent in appearance after laser welding and a color tone and has sufficient impact resistance as a resin member. As a result of intensive studies, the present inventors have found that the above problems can be solved by controlling a thermoplastic resin composition containing rubber-containing graft copolymer to have appropriate reflectance in the visible light and absorptivity in the near-infrared region, and have completed the present invention.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 17, 2020
    Assignee: Techno-UMG Co., Ltd.
    Inventors: Ichiro Kamata, Hiroyuki Atsuta
  • Patent number: 10590223
    Abstract: A polyphenylene ether resin composition includes (A) a modified polyphenylene ether that is end-modified with a substituent having a carbon-carbon unsaturated double bond, and (B) a crosslinking agent having a carbon-carbon unsaturated double bond. The crosslinking agent serving as component (B) includes from 50 to 100 mass % of (B-1) divinylbenzene and (B-2) polybutadiene. Components (A) and (B) are included in a ratio therebetween, expressed as the mass ratio (A):(B), of from 65:35 to 95:5. Components (B-1) and (B-2) are included in a ratio therebetween, expressed as the mass ratio (B-1):(B-2), of from 1:100 to 1.5:1.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: March 17, 2020
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventors: Yuki Kitai, Hiroaki Fujiwara, Hirosuke Saito